MeSH tree: D04.345.295
A case report published in Eurosurveillance on an adult with an imported case of leprosy in Ireland shows that there are notable challenges in tackling the disease in settings where it is rare.
Jan 23, 2025
0
15
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared ...
Jan 15, 2025
0
48
For patients with a history of overt hepatic encephalopathy (OHE), rifaximin monotherapy (MT) results in significantly fewer OHE episodes than lactulose (LAC) MT, according to a study presented at the annual meeting of the ...
Oct 28, 2024
0
16
A new study has found that an antibiotic for liver disease patients could expose them to greater risk of a dangerous superbug.
Oct 24, 2024
0
84
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute ...
Jun 27, 2024
0
50
Personalized "cocktails" of antibiotics, probiotics and prebiotics hold great promise in the treatment of a common form of irritable bowel syndrome (IBS), according to research presented at the ESCMID Global Congress (formerly ...
Apr 26, 2024
0
100
New research indicates that antibiotics can effectively target bacteria in the gut that harbor the virus that causes COVID-19 and produce toxin-like peptides that contribute to COVID-19-related symptoms.
Mar 20, 2024
0
38
Tuberculosis, the main cause of death due to a single pathogen globally, causes more than 1.5 million deaths each year. New research from the University of Cincinnati finds that being in prison or being a former prisoner ...
Feb 9, 2024
0
58
In a new paper published in Cancer Research, researchers at MUSC Hollings Cancer Center have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can restore the effectiveness ...
Feb 6, 2024
0
41
A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast ...
Dec 6, 2023
0
34
